- Home
- VRTX
as of 02-26-2026 9:36am EST
$480.99
$1.84
-0.38%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 115.7B | IPO Year: | 2006 |
| Target Price: | $526.79 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 15.32 | EPS Growth: | 836.54 |
| 52 Week Low/High: | $362.50 - $519.68 | Next Earning Date: | 05-15-2026 |
| Revenue: | $2,488,652,000 | Revenue Growth: | 46.20% |
| Revenue Growth (this year): | 11.1% | Revenue Growth (next year): | 10.23% |
| P/E Ratio: | 31.52 | Index: | |
| Free Cash Flow: | 3.2B | FCF Growth: | N/A |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
Sachdev Amit
Sell
EVP Chief Patient & Ext Af Off
VRTX Feb 19, 2026
Avg Cost/Share
$467.83
Shares
58,613
Total Value
$27,479,583.09
Owned After
74,883
Ambrose Kristen
Sell
SVP & Chief Accounting Officer
VRTX Feb 18, 2026
Avg Cost/Share
$473.68
Shares
1,276
Total Value
$604,415.68
Owned After
7,750
Tatsis Ourania
Sell
EVP, Chief Reg. & Quality Off.
VRTX Feb 18, 2026
Avg Cost/Share
$473.68
Shares
368
Total Value
$174,314.24
Owned After
48,650
SEC Form 4
Atkinson Edward Morrow III
Sell
EVP, Chief Technical Ops. Off.
VRTX Feb 18, 2026
Avg Cost/Share
$473.68
Shares
817
Total Value
$386,996.56
Owned After
20,727
SEC Form 4
Biller Jonathan
Sell
EVP and Chief Legal Officer
VRTX Feb 18, 2026
Avg Cost/Share
$473.68
Shares
1,244
Total Value
$589,257.92
Owned After
15,748
SEC Form 4
Bunnage Mark E.
Sell
EVP, Chief Scientific Officer
VRTX Feb 18, 2026
Avg Cost/Share
$473.68
Shares
1,182
Total Value
$559,889.76
Owned After
8,486
SEC Form 4
Ambrose Kristen
Sell
SVP & Chief Accounting Officer
VRTX Feb 17, 2026
Avg Cost/Share
$489.46
Shares
3,114
Total Value
$1,524,178.44
Owned After
7,750
Tatsis Ourania
Sell
EVP, Chief Reg. & Quality Off.
VRTX Feb 17, 2026
Avg Cost/Share
$489.46
Shares
609
Total Value
$298,081.14
Owned After
48,650
SEC Form 4
Atkinson Edward Morrow III
Sell
EVP, Chief Technical Ops. Off.
VRTX Feb 17, 2026
Avg Cost/Share
$489.46
Shares
2,031
Total Value
$994,093.26
Owned After
20,727
SEC Form 4
Biller Jonathan
Sell
EVP and Chief Legal Officer
VRTX Feb 17, 2026
Avg Cost/Share
$489.46
Shares
2,476
Total Value
$1,211,902.96
Owned After
15,748
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 19, 2026 | Sell | $467.83 | 58,613 | $27,479,583.09 | 74,883 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 18, 2026 | Sell | $473.68 | 1,276 | $604,415.68 | 7,750 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 18, 2026 | Sell | $473.68 | 368 | $174,314.24 | 48,650 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 18, 2026 | Sell | $473.68 | 817 | $386,996.56 | 20,727 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 18, 2026 | Sell | $473.68 | 1,244 | $589,257.92 | 15,748 | |
| Bunnage Mark E. | VRTX | EVP, Chief Scientific Officer | Feb 18, 2026 | Sell | $473.68 | 1,182 | $559,889.76 | 8,486 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 17, 2026 | Sell | $489.46 | 3,114 | $1,524,178.44 | 7,750 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 17, 2026 | Sell | $489.46 | 609 | $298,081.14 | 48,650 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 17, 2026 | Sell | $489.46 | 2,031 | $994,093.26 | 20,727 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 17, 2026 | Sell | $489.46 | 2,476 | $1,211,902.96 | 15,748 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
📊
AI Sentiment
Positive
6/10
Motley Fool
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns
📊
AI Sentiment
Positive
7/10
MT Newswires
Vertex Pharmaceuticals Insider Sold Shares Worth $472,395, According to a Recent SEC Filing
âž–
AI Sentiment
Neutral
5/10
MT Newswires
Vertex Pharmaceuticals Insider Sold Shares Worth $1,064,297, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Simply Wall St.
Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case
📈
AI Sentiment
Highly Positive
8/10
Compare VRTX vs Leading Stocks
See how VRTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.